Business · 30/01/2007Updated: 10/17/2026 · 1 min read
FDA Announces Proposed Collection of Information for Biological Product Deviations Reporting
Summary
The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, focusing on the reporting of biological product deviations in manufacturing, as required by the Paperwork Reduction Act of 1995.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →